Puma Biotechnology Inc revenue growth has been varied year-over-year.

What is PBYI's revenue growth rate?

Historical revenue data is available for Puma Biotechnology Inc to analyze growth trends.

How fast is PBYI earnings growing?

Earnings growth data is available for Puma Biotechnology Inc analysis.

What is PBYI's profit margin?

Profit margin data is available for Puma Biotechnology Inc.

PBYI Revenue & Earnings Growth Analysis 2026 - Is Puma Biotechnology Inc Growing?

Growth Summary

Puma Biotechnology Inc (PBYI) has experienced challenges in growth. The company operates in the Healthcare sector, specifically in the Biotechnology industry.

Over the past 4 years, Puma Biotechnology Inc has achieved a revenue compound annual growth rate (CAGR) of 44.7%.

Latest Revenue

$230.47M

Net Income

$30.28M

5-Year Revenue CAGR

44.7%

4 years of data

Net Margin

N/A

Latest period

Revenue Growth Over Time

Historical revenue and profitability trends for Puma Biotechnology Inc

The chart above illustrates Puma Biotechnology Inc's revenue trajectory over the past 4 years. The revenue pattern shows the challenges the company has faced in recent periods.

Year-over-Year Growth Rates

Annual percentage change in revenue and earnings

Growth rates provide insight into the momentum of Puma Biotechnology Inc's business.

Profit Margin Trends

How efficiently Puma Biotechnology Inc converts revenue into profit

Understanding Profit Margins

Profit margins reveal how much of each dollar of revenue Puma Biotechnology Inc retains at different stages:

Gross Margin (N/A%): What remains after direct production costs
Operating Margin (N/A%): Profit from core operations before interest and taxes
Net Margin (N/A%): Final profit after all expenses

Future Growth Outlook

Analyst estimates and forward-looking indicators

EPS Estimate 2026

$0.40

Current: $0.62

EPS Estimate 2027

$0.65

62.5% expected growth

Price Target

$5.00

Analyst consensus

What Analysts Are Saying

Wall Street analysts project Puma Biotechnology Inc to continue growing earnings in the coming year. The consensus analyst rating is 2.5 based on 2 analysts.

Growth Analysis Conclusion

Based on our comprehensive analysis, Puma Biotechnology Inc (PBYI) demonstrates declining growth characteristics.

Key Takeaways:

Revenue Growth:, 44.7% CAGR over 4 years
Profitability: demonstrates the company is profitable
Efficiency:

Investment Considerations

This growth analysis provides a comprehensive view of Puma Biotechnology Inc's historical performance and future outlook. Investors should consider these growth metrics alongside valuation, competitive positioning, and broader market conditions when making investment decisions. Past performance does not guarantee future results.